dm+d

Unassigned

New Medicines

Frontotemporal dementia due to heterozygous mutations in the progranulin gene (FTD-GRN)

Information

New molecular entity
GlaxoSmithKline
Alector and GlaxoSmithKline

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

A microglia activating recombinant human anti-human sortilin (SORT1) monoclonal antibody, given 4-weekly.
FTD is much less common than Alzheimers disease and vascular dementia. Figures vary, but it probably accounts for less than 5% of all dementia. The incidence of FTD is estimated to be 1.61 to 4.1 cases per 100,000 people annually [1]. GRN-FTD represents about 5% of all FTD, and 20% of FTD in which the family history is positive. It is inherited in an autosomal dominant manner [2].
Frontotemporal dementia due to heterozygous mutations in the progranulin gene (FTD-GRN)
Intravenous infusion